dexmedetomidine has been researched along with Intestinal Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, H; Jia, J; Tu, W; Wu, Y; Xi, W; Xu, Y; Yang, J | 1 |
| Deng, LH; Hua, YP; Huang, CY; Huang, WQ; Liu, KX; Wang, ZX | 1 |
1 trial(s) available for dexmedetomidine and Intestinal Diseases
| Article | Year |
|---|---|
Dexmedetomidine reduces intestinal and hepatic injury after hepatectomy with inflow occlusion under general anaesthesia: a randomized controlled trial.
Topics: Adult; Aged; Amine Oxidase (Copper-Containing); Analgesics, Non-Narcotic; Anesthesia, General; Biomarkers; Dexmedetomidine; Double-Blind Method; Female; Hepatectomy; Humans; Intestinal Diseases; Intestines; Liver; Liver Diseases; Male; Middle Aged; Prospective Studies; Reperfusion Injury | 2014 |
1 other study(ies) available for dexmedetomidine and Intestinal Diseases
| Article | Year |
|---|---|
Dexmedetomidine Resists Intestinal Ischemia-Reperfusion Injury by Inhibiting TLR4/MyD88/NF-κB Signaling.
Topics: Animals; Biomarkers; Blotting, Western; Caco-2 Cells; Cell Survival; Dexmedetomidine; Humans; Intestinal Diseases; Intestines; Male; Myeloid Differentiation Factor 88; NF-kappa B; Protective Agents; Random Allocation; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Signal Transduction; Toll-Like Receptor 4 | 2021 |